We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Verve Therapeutics (VERV - Free Report) shares rallied 13.8% in the last trading session to close at $12.99. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 12.1% loss over the past four weeks.
The surge in the stock price is likely to be an outcome of the positive momentum built around the company's gene editing pipeline. Verve announced that it will be presenting an interim data from its ongoing heart-1 phase Ib study of VERVE-101 for patients with high-risk heterozygous familial hypercholesterolemia at American Heart Association’s Scientific Sessions 2023, in November.
This biotechnology firm is expected to post quarterly loss of $0.91 per share in its upcoming report, which represents a year-over-year change of -15.2%. Revenues are expected to be $3.04 million, up 226.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Verve Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on VERV going forward to see if this recent jump can turn into more strength down the road.
Verve Therapeutics belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Scynexis (SCYX - Free Report) , closed the last trading session 11.5% lower at $1.93. Over the past month, SCYX has returned -35.3%.
For Scynexis, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.29. This represents a change of +146.8% from what the company reported a year ago. Scynexis currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?
Verve Therapeutics (VERV - Free Report) shares rallied 13.8% in the last trading session to close at $12.99. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 12.1% loss over the past four weeks.
The surge in the stock price is likely to be an outcome of the positive momentum built around the company's gene editing pipeline. Verve announced that it will be presenting an interim data from its ongoing heart-1 phase Ib study of VERVE-101 for patients with high-risk heterozygous familial hypercholesterolemia at American Heart Association’s Scientific Sessions 2023, in November.
This biotechnology firm is expected to post quarterly loss of $0.91 per share in its upcoming report, which represents a year-over-year change of -15.2%. Revenues are expected to be $3.04 million, up 226.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Verve Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on VERV going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Verve Therapeutics belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Scynexis (SCYX - Free Report) , closed the last trading session 11.5% lower at $1.93. Over the past month, SCYX has returned -35.3%.
For Scynexis, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.29. This represents a change of +146.8% from what the company reported a year ago. Scynexis currently has a Zacks Rank of #3 (Hold).